Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, ...

(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...